Authors: Meletios A. Dimopoulos, A. Keith Stewart, Saad Z. Usmani, Thierry Facon, Nizar J. Bahlis, et al. (POLLUX Phase 3 Investigators)
Demonstrated a statistically significant 27% reduction in risk of death (Hazard Ratio 0.73, p = 0.004) and a 4-fold increase in Minimal Residual Disease (MRD) negativity at 10^-5 sensitivity.
Key Quantitative & Theoretical Takeaway: Median overall survival reached 67.6 months in the D-Rd group versus 51.8 months in the Rd control group despite subsequent daratumumab crossover.
In the primary analysis of the phase 3 POLLUX trial, daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. Here we report the final overall survival analysis.
At 79.7 months median follow-up, D-Rd achieved a median overall survival of 67.6 months compared to 51.8 months with Rd alone (Hazard Ratio 0.73; 95% CI 0.58 to 0.91; P = 0.004).
Replace arxiv.org with nujan.app on any arXiv URL (for example, https://nujan.app/abs/2006.11239) to open the PDF and AI research partner side-by-side.